Cantor Fitzgerald Predicts Amgen FY2025 Earnings

Amgen Inc. (NASDAQ:AMGN) – Stock analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Amgen in a research note issued on Tuesday, April 22nd. Cantor Fitzgerald analyst C. Gould anticipates that the medical research company will earn $20.50 per share for the year. Cantor Fitzgerald has a “Neutral” rating and a $305.00 price target on the stock. The consensus estimate for Amgen’s current full-year earnings is $20.62 per share.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%.

A number of other research analysts have also recently commented on the stock. Johnson Rice set a $294.00 price target on shares of Amgen in a report on Wednesday, March 5th. StockNews.com downgraded shares of Amgen from a “strong-buy” rating to a “buy” rating in a research note on Thursday, April 17th. Citigroup reaffirmed a “neutral” rating on shares of Amgen in a research note on Wednesday, February 5th. Piper Sandler Companies reissued an “overweight” rating and issued a $310.00 price objective on shares of Amgen in a research note on Thursday, January 2nd. Finally, Bank of America raised their price objective on Amgen from $275.00 to $294.00 and gave the stock an “underperform” rating in a report on Wednesday, March 5th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Amgen presently has a consensus rating of “Hold” and a consensus price target of $310.57.

Amgen Stock Performance

AMGN stock opened at $280.84 on Thursday. Amgen has a twelve month low of $253.30 and a twelve month high of $346.85. The firm has a market cap of $150.99 billion, a price-to-earnings ratio of 37.20, a PEG ratio of 2.63 and a beta of 0.59. The business’s fifty day simple moving average is $301.52 and its two-hundred day simple moving average is $292.83. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Virtu Financial LLC purchased a new stake in shares of Amgen in the 3rd quarter valued at $1,588,000. Morse Asset Management Inc acquired a new position in Amgen during the third quarter valued at $806,000. Tudor Financial Inc. purchased a new stake in Amgen in the third quarter valued at $3,281,000. World Investment Advisors LLC grew its position in Amgen by 48.4% during the 3rd quarter. World Investment Advisors LLC now owns 11,083 shares of the medical research company’s stock worth $3,571,000 after purchasing an additional 3,616 shares during the period. Finally, Arvest Bank Trust Division purchased a new position in shares of Amgen during the 3rd quarter valued at about $408,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Amgen

In other Amgen news, EVP David M. Reese sold 8,711 shares of the company’s stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $293.22, for a total transaction of $2,554,239.42. Following the transaction, the executive vice president now owns 62,147 shares in the company, valued at approximately $18,222,743.34. This represents a 12.29 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Jonathan P. Graham sold 25,045 shares of Amgen stock in a transaction on Friday, February 7th. The stock was sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the sale, the executive vice president now owns 28,987 shares of the company’s stock, valued at $8,496,669.44. The trade was a 46.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 69,341 shares of company stock worth $20,644,335. Insiders own 0.69% of the company’s stock.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be issued a $2.38 dividend. This represents a $9.52 annualized dividend and a yield of 3.39%. The ex-dividend date of this dividend is Friday, May 16th. Amgen’s dividend payout ratio is presently 126.09%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.